Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BMSN maybe not yet. but 50 million shares @ 10 cents a share is 5 million dollars. current cap at 695,000. do the math. good luck BMSN
BMSN not sure what you consider very few shares.
RGBP
As of June 30, 2017 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090.
BMSN
RGBP
FinancialBuzz.com News Commentary
NEW YORK, November 17, 2017 /PRNewswire/ --
According to a report by Grand View Research (GVR), the global biotechnology market is expected to reach USD 727.1 billion by 2025. Major technological advancements in segments such as regenerative medicine and genetics in diagnostics are important drives for the future of biotechnology. Innovative companies in the industry are engaged in large clinical trials and strong R&D investments for cancer therapeutics, as oncology is one of the most promising areas of focus in the biotech industry. Regen Biopharma, Inc. (OTC: RGBP), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), ImmunoGen, Inc. (NASDAQ: IMGN).
"Rising incidence of oncology diseases is anticipated to drive the demand for next-generation cancer diagnostic tests. These tests are expected to facilitate early diagnosis and enable efficient prognosis of various forms of cancer, which in turn, is expected to positively influence progress of this vertical over the forecast period. Development and introduction of product offerings by a number of large entities is a significant factor expected to provide lucrative growth avenues to this market, active participation of global organizations, such as National Cancer Institute, Cancer Research Institute, National Foundation for Cancer Research, and Cancer Research UK, are supportive of the projected sector progress," GVR reports.
Regen BioPharma, Inc. (OTCQB: RGBP) announced breaking news after the market close that it has, "commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders."
"The rationale for activating the NR2F6 nuclear receptor (also known as a checkpoint) is straightforward - if inhibiting the checkpoint activates the immune system and thus helps kill cancer cells, then conversely, activating the checkpoint should suppress the immune system and thus be useful in diseases where the immune system is over-activated, such as rheumatoid arthritis, lupus, colitis and many other autoimmune diseases," says David Koos, Ph.D., Chairman and CEO of Regen. "Our program stands out because we are working with small molecules delivered in pill form. Other biotechnology companies are focused on antibodies that have much more cumbersome delivery methods (hospital stays with IV injections, etc.). The benefits of small molecules are many, including cost of manufacturing, flexibility in dosing and routes of administration, potential control of toxicity and intellectual property protection."
BMSN not sure where you are coming up with 30 million shares. The last I saw, from June is 50 million. If you have something that contradicts this, please post. thanks
RGBP
As of June 30, 2017 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090.
BMSN folks will realize how undervalued BMSN is, holding 50 million shares of rgbp. and steering the ship. Do the math. This should be trading at .0005. another solid volume day. good luck in my opinion. BMSN
BMSN if rgbp is trading at .07 or 7 cents, BMSN is worth at LEAST 3.5 million dollars, based on owning 50 million shares. in other words the valuation of BMSN should be 5 times what it is trading at, or .0005. imo glta BMSN
RGBP if rgbp is trading at .07 or 7 cents, BMSN is worth at LEAST 3.5 million dollars, based on owning 50 million shares. in other words the valuation of BMSN should be 5 times what it is trading at, or .0005. imo glta RGBP
BMSN
SAN DIEGO, November 16, 2017 /PRNewswire/ --
18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders
"The rationale for activating the NR2F6 nuclear receptor (also known as a checkpoint) is straightforward - if inhibiting the checkpoint activates the immune system and thus helps kill cancer cells, then conversely, activating the checkpoint should suppress the immune system and thus be useful in diseases where the immune system is over-activated, such as rheumatoid arthritis, lupus, colitis and many other autoimmune diseases," says David Koos, Ph.D., Chairman and CEO of Regen. "Our program stands out because we are working with small molecules delivered in pill form. Other biotechnology companies are focused on antibodies that have much more cumbersome delivery methods (hospital stays with IV injections, etc.). The benefits of small molecules are many, including cost of manufacturing, flexibility in dosing and routes of administration, potential control of toxicity and intellectual property protection."
There are currently about 9 companies working on activating immune checkpoints, but Regen appears to be the sole company known to be working on utilizing small molecules to activate immune checkpoints
(https://www.biocentury.com/bc-innovations/strategy/2017-08-10/how-immuno-oncology-targets-are-spawning-new-therapies-).
https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc--Chairman-Discusses-the-Rationale-for-Pursuing-Autoimmune-Indications-by-Activating-the-Nuclear-Receptor-NR2F6?id=175696&b=y
Looks grim! cybl imo
BMSN Regen mentioned with the big boys.
NOVEMBER 15, 2017 BY SAMBIT KUMAR
Global Sickle Cell Anemia Drug Market Analysis & Research, Key Players, Production Information Analysis and Forecasts to 2022
Research N Reports has proclaimed the addition of a new market intelligence report, titled “Global Sickle Cell Anemia Drug Market.” This report studies Sickle Cell Anemia Drug in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering GlycoMimetics, Bluebird bio, GlaxoSmithKline, Mast Therapeutics, Bayer AG, Eli Lilly, Regen biopharma etc. It also provides essential information about leading companies, such as product specification, financial overview, business overview, contact information, and recent developments.
http://www.satprnews.com/2017/11/15/global-sickle-cell-anemia-drug-market-analysis-research-key-players-production-information-analysis-and-forecasts-to-2022/
BMSN aside from the Huge pile of shares that the company has of RGBP shares, and the voting power, this gives me hope also. Koos has a lot of personal shares he bought years ago. He paid a lot more than they are worth, and he has never sold any through the years. Still have faith in this.
Koos (David Raymond) 72.7 M $7.3 K 99.94 1.05% Low
BMSN imo
Soup du Jour. Granny Clampett cooking up a big cauldron of Opossum soup with chitlins. Enjoy!
CYBL staunch volume out the gate. c'mon Schmidtty, hit us with a huge government contract or marijuana lighting news. go CYBL
BMSN
Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs
SAN DIEGO, November 8, 2017 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor. In addition, the Company recently reported that its NR2F6 medicinal chemistry program identified key structural elements in small molecules that make them active and specific towards the NR2F6 target.
These two programs are integrally linked. Success in determining the structure of NR2F6 will inform future work on medicinal chemistry, as well as confirm the exact nature of the interaction between Regen's small molecules and NR2F6.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and Lupus.
"The object of the three-dimensional x-ray structure program is to shed light on exactly how our small molecules bind to and modulate NR2F6 activity. Imagine the NR2F6 nuclear receptor (protein) has a specific pocket where activators bind. We don't know the shape of that pocket, although we are beginning to infer it from the key structural elements of our small molecules that bind and activate it. With the actual structural data in hand from the three-dimensional x-ray structure, we will be able to see nuances that will both explain our success so far and will guide us as we make more small molecules. This will also help us improve on the small molecules we have made so far," said Harry Lander, President and Chief Scientific Officer of Regen BioPharma Inc.
"The three-dimensional x-ray structure program, coupled with our medicinal chemistry program will enhance Regen's drug development process. These two programs linked together will give us a much clearer picture of what is actually happening at the molecular level," said David Koos, Ph.D., Chairman and CEO of Regen BioPharma Inc. "That, in turn, will help any of our potential co-development partners feel more comfortable with our mechanism of action."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is targeting the immunotherapy space, seeking to rapidly advance small molecule immunological therapies to treat cancer and autoimmunity through pre-clinical and Phase I/ II clinical trials. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
BMSN
BMSN solid day. Folks see how undervalued this is along with RGBP. BMSN has the steering wheel and a Lion's Load of RGBP shares. Along with a lot of valuable patents Lets hope for a miracle . in my opinion good luck to all! BMSN
RGBP
Maybe a merger in the offing ?
Hope so Mort!
RGBP
As of June 30, 2017 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090
Consider if RGBP goes back to a quarter a share, or if there was a buyout at that price. that would make BMSN worth at least 12.5 million, or .0020 valuation approximately. all in my opinion good luck all
RGBP
BMSN
RGBP
As of June 30, 2017 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090
Consider if RGBP goes back to a quarter a share, or if there was a buyout at that price. that would make BMSN worth 12.5 million, or .0020 valuation approximately.
Asleep, yes, Morte? not yet imo good luck to you BMSN
BMSN non reporting companies end up with the stop sign on otc markets. lots of companies have the stop sign. as long as it doesn't go to a skull and crossbones. Meanwhile another 6 million shares traded today, which is the average. imo fewer folks have a larger portion of the shares. still have lots of faith here, rounded the corner of 200 million + shares myself.. This is why I still have lots of hope for at least .0015-0020:
RGBP
As of June 30, 2017 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090
Consider if RGBP goes back to a quarter a share, or if there was a buyout at that price. that would make BMSN worth 12.5 million, or .0020 valuation approximately.
The news this week about 2 blokes joining the advisory board is interesting. one is from Lily and one from CVS pharma. All of it is a long shot, of course. but not far fetched in my opinion good luck to all and have a great weekend. BMSN
BMSN it would be nice to hear something by end of year. still holding hope! good luck BMSN imo
BMSN I agree. .001 minimum. all in my opinion. good luck! bmsn
ELIO the stock has slipped below 5 bucks a share. It will be below a dollar within a year imo. No earnings, debt, and possible class action suit. Not in this stock, and wont be. I already lost 100 bucks on the deposit. go ELIO in my opinion
BMSN 44 million T form buy at .000099. that aint retail in my opinion. Lets hope for a juggernaut runner like days yore. good luck imo BMSN
BMSN the tides are turning. volume before price. Looking to add more of this lowly offering. do your due dilligence before buying here. may be a long wait. but BMSN is steering the ship with a cut of the booty. all in my opinion good luck to all! BMSN
BMSN Feverish volume out the gate. Stay tuned for news. imo glta BMSN
ELIO, put the shirt into mothballs. you can break it out in 3 years when you get your car lol. imo the slow bleed off continues. Paul Elio has likely made a fortune from flogging shares on the way down. This will be in the 4's very soon, touched 5 bucks today. A conundrum if you bought above 10 bucks, do you sell and buy back in much lower, or do you hang in there and wait it out. I am sure the folks that paid 50 bucks a share and more are a little nauseous. good luck imo ELIO
ELIO I got sick of waiting for my elio so I bought a honda insight hybrid from 2000. LOVE IT! handles like a little sports car, gets over 55 mpg combined. The bleed off continues on the stock, approaching 5 bucks and dropping. It will be in the 4 dollar range soon, probably by years end. I dont see the folks that bought over 50 bucks a share will see there money. ever. just my opinion, good luck to all go elio, still got my deposit down lol
ELIO down 75 percent this year, 20 bucks to 5 bucks a share. People bought this at 70 bucks a share. Sad that ELIO is still taking deposits and forgetting about the deposits already taken. I smell a class action suit coming. I have had 100 dollar deposit down for 4 years now. imo good luck elio
BMSN staunch volume right out of the gate. go BMSN
BMSN my target is .0025. imo glta BMSN on big news
BMSN yeah it takes 100 percent jump to move here, so hard to move off the bottom. But the lowly BMSN steering the boat with a nice chunk of the booty. imo glta BMSN
RGBP
As of June 30, 2017 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090.
Soup Du Jour- Granny Clampett cooking a cauldron of opossum soup
BMSN any evidence of a reverse split or just a hunch? BMSN
BMSN yeah, Kooster and da Science team still has a minimum of 120 million shares. expect a spin off or something. He aint gonna let Grandpa to die without a going away party.... in my opinion. If RGBP rages, BMSN will follow suit. If RGBP reaches 20 cents a share, BMSN is worth 10 million minimum. imo glta BMSN
RGBP
As of June 30, 2017 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090.
BMSN yes, double the share count of the epic run. I still see .0025 to 0050 possible IF big news comes. Here is my reason for any optimism. Koos has imbedded value into BMSN through RGBP imo glta BMSN
RGBP
As of June 30, 2017 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090.
BMSN yes from .0002 to .016. also ran from high trips to .0095. buckle up imo glta BMSN
BMSN another 9.7 million shares traded today. Koos on da loose! go BMSN imo